Search - tctmd.com

Displaying 101 - 120 of 267

Sort: Relevancy | Date

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

Shelley Wood

November 14, 2017

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

‘A Healthy Brexit’? How a Split From EU Could Affect UK Health System

Yael L. Maxwell

October 02, 2017

News Daily News

Physical Activity of Any Ilk Cuts CVD, Deaths in Global Study: PURE

Shelley Wood

September 22, 2017

News Opinion Fellow Talk

Cost Awareness and Fellowship Education

Amit K. Gupta, MBBS, MD

August 31, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Biomedical Research in CVD: More Investment Today Will Yield Long-term Rewards

Caitlin E. Cox

June 29, 2017

News Daily News

Cardiac Testing in Chest Pain Patients Without Ischemia Does Not Reduce Acute MI Admissions

Michael O'Riordan

June 28, 2017

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Industry News

FDA Grants Market Clearance to Ra Medical Systems for New Peripheral Artery Disease Treatment

June 06, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Industry News

Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting

April 26, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

Advertisement

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Live From Denver: TCT 2017, Day Two

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

‘A Healthy Brexit’? How a Split From EU Could Affect UK Health System

Physical Activity of Any Ilk Cuts CVD, Deaths in Global Study: PURE

Cost Awareness and Fellowship Education

Evolocumab Not Cost-Effective at Current List Price

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Biomedical Research in CVD: More Investment Today Will Yield Long-term Rewards

Cardiac Testing in Chest Pain Patients Without Ischemia Does Not Reduce Acute MI Admissions

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

FDA Grants Market Clearance to Ra Medical Systems for New Peripheral Artery Disease Treatment

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content